Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe

International Journal of Stroke

Volumn 7, Issue 8, 2012, Pages 615-622

  Karlinski, Michal ^a   Kobayashi, Adam ^a   Mikulik, Robert ^b   Sanak, Daniel ^c   Wahlgren, Nils ^d   Czlonkowska, Anna ^a,e   Brozman, Miroslav ^f   Svigelj, Viktor ^f   Csiba, Laszlo ^f   Korv, Janika ^f   Demarin, Vida ^f   Jatuzis, Dalius ^f   Vilionskis, Alexandras ^f   Krespi, Yakup ^f  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f NONE

Author keywords

Acute stroke; Alteplase; Off label use; Thrombolysis; Treatment outcome

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL EUROPE; COMORBIDITY; DIABETES MELLITUS; DISEASE REGISTRY; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; EASTERN EUROPE; EUROPE; FEMALE; HUMAN; LICENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; EUROPE, EASTERN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ODDS RATIO; OFF-LABEL USE; REGISTRIES; STROKE; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84858801418     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00733.x     Document Type: Article

References (25)

1. van Wijngaarden JD, Dirks M, Huijsman R, Niessen LW, Fabbricotti IN, Dippel DW. Hospital rates of thrombolysis for acute ischemic stroke: the influence of organizational culture. Stroke 2009; 40:3390-3392.
2. Mikulík R, Vaclavik D, Sanak D etal. A nationwide study on topography and efficacy of the stroke treatment network in the Czech Republic. J Neurol 2010; 257:31-37.
3. Actilyse. The European Medicines Agency (EMEA). Available at http://www.ema.europa.eu/pdfs/human/referral/Actilyse/334602en.pdf (accessed December 2010).
4. De Keyser J, Gdovinová Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007; 38:2612-2618.
5. Rubiera M, Ribo M, Santamarina E etal. Is it time to reassess the SITS-MOST criteria for thrombolysis?: a comparison of patients with and without SITS-MOST exclusion criteria. Stroke 2009; 40:2568-2571.
6. Wahlgren N, Ahmed N, Dávalos A etal. Thrombolysis with alteplase 3-4·5h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372:1303-1309.
7. Lees KR, Bluhmki E, von Kummer R etal. ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695-1703.
8. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age - a systematic review across cohort studies. Age Ageing 2006; 35:572-580.
9. Meseguer E, Labreuche J, Olivot JM etal. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review. Age Ageing 2008; 37:107-111.
10. Ford GA, Ahmed N, Azevedo E etal. Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010; 41:2568-2574.
11. Mishra NK, Ahmed N, Andersen G etal. for the VISTA and SITS collaborators. Thrombolysis in the very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010; 341:c6046.
12. Wahlgren N, Ahmed N, Dávalos A etal. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275-282.
13. Hacke W, Kaste M, Fieschi C etal. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
14. Czlonkowska A, Skowrońska M, Niewada M. Stroke service in Central and Eastern Europe. Int J Stroke 2007; 2:276-278.
15. Kobayashi A, Czlonkowska A, Ahmed N etal. Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry. Acta Neurol Scand 2010; 122:229-236.
16. Meretoja A, Putaala J, Tatlisumak T etal. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41:1450-1458.
17. Mishra NK, Davis S, Kaste M, Lees K. for the VISTA collaboration. Comparison of outcomes following thrombolytic therapy amongst patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 2010; 33:2531-2537.
18. Mishra NK, Lyden P, Grotta JC, Lees KR; VISTA Collaborators. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010; 41:2612-2617.
19. Wardlaw JM, Sandercock PA, Murray V. Should more patients with acute ischaemic stroke receive thrombolytic treatment? BMJ 2009; 339:b4584.
20. Ahmed N, Wahlgren N, Grond M etal. for the SITS Investigators. Implementation and outcome of thrombolysis with alteplase 3-4·5h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9:866-874.
21. Sare GM, Geeganage C, Bath PM. High blood pressure in acute ischaemic stroke - broadening therapeutic horizons. Cerebrovasc Dis 2009; 27(Suppl. 1):156-161.
22. Ahmed N, Wahlgren N, Brainin M etal. for the SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40:2442-2449.
23. Prabhakaran S, Rivolta J, Vieira JR etal. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2010; 67:559-563.
24. Bruno A, Levine SR, Frankel MR etal. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002; 59:669-674.
25. Ahmed N, Dávalos A, Eriksson N etal. for the SITS Investigators. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 2010; 67:1123-1130.